Hexamethylmelamine as Consolidation Treatment for Patients with Advanced Epithelial Ovarian Cancer in Complete Response after First-Line Chemotherapy

다국어 초록 (Multilingual Abstract)

The aim of this study was to assess the efficacy of consolidation therapy with hexamethylmelamine

(HMM) in patients with advanced epithelial ovarian cancer (EOC).

Patients treated at our hospital between January 1997 and November 2006 and in

documented clinical complete response from advanced ovarian cancer following

front-line platinum-based therapy were retrospectively analyzed. The patients treated

with HMM were compared to the patients of matched counterpart without consolidation

therapy. Of 102 patients enrolled, 49 were treated with HMM and 53 received

no consolidation treatment. For patients with HMM and observed patients, the mean

age were 54.6 and 55.6 yr; the distribution of stage was similar (P=0.977); the optimal

surgery was performed in 36 (73.5%) and 44 (83%) (P=0.336); the recurrence

rate were 27 (55.1%) and 33 (62.3%) (P=0.463); and the median progression-free

survival were 38 months and 21 months for patients with HMM and observed patients

(P=0.235). No treatment-related adverse events were reported during the followup

period. Although this study failed to show the significant survival benefit of consolidation

therapy with HMM in patients with advanced EOC, we consider that our

study can contribute data to investigate the effectiveness of consolidation therapy

in epithelial ovarian cancer.

참고문헌 (Reference)

1 De Placido S, "Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study" 22 : 2635-2642, 2004

2 McMeekin DS, "Timing isn’t everything: an analysis of when to start salvage chemotherapy in ovarian cancer" 95 : 157-164, 2004

3 Markman M, "Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer" 103 : 195-198, 2006

4 Markman M, "Second-line treatment of ovarian cancer" 5 : 26-35, 2000

5 Conte PF, "Second-line treatment and consolidation therapies in advanced ovarian cancer" 11 (11): 52-56, 2001

6 Podratz KC, "Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma" 29 : 274-282, 1988

7 Makar AP, "Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis" 79 : 1002-1010, 1992

8 Eisenhauer EA, "Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients" 8 : 963-968, 1997

9 Ozols RF, "Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study" 21 : 3194-3200, 2003

10 Markman M, "Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial" 21 : 2460-2465, 2003

11 Rustin GJ, "Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125" 15 : 172-176, 1997

12 Rothenberg ML, "Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326)" 82 : 317-322, 2001

13 Chiara S, "Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. The Gruppo Oncologico Nord Ovest" 31A : 296-301, 1995

14 Alberts DS, "Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group" 14 : 224-228, 2004

15 Ames MM, "Hexamethylmelamine: pharmacology and mechanisms of action" 18 (18): 3-14, 1991

16 Vergote I, "Hexamethylmelamine as second-line therapy in platinresistant ovarian cancer" 47 : 282-286, 1992

17 Manetta A, "Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature" 66 : 20-26, 1997

18 Thigpen JT, "Current controversies in ovarian cancer: maintenance chemotherapy as standard care. In: American Society of Clinical Oncology, 2004 educational book" 281-284, 2004

19 Ozols RF, "Current controversies in ovarian cancer: maintenance chemotherapy and neoadjuvant chemotherapy as standard care. In: American Society of Clinical Oncology" 268-275, 2004

20 Bast RC Jr, "CA 125: the past and the future" 13 : 179-187, 1998

21 Mano MS, "Atalay G, Lago LD, Cardoso F, Piccart M. Remaining controversies in the upfront management of advanced ovarian cancer" 14 : 707-720, 2004

22 Gadducci A, "Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study" 68 : 150-155, 1998

23 Lee CR, "Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy" 49 : 932-953, 1995

24 Malik IA, "Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer" 31 : 69-73, 2001

25 Markman M, "Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial" 69 : 226-229, 1998